Day One | Tuesday, November 6, 2018
Registration Opens and Continental Breakfast
Chairperson's Welcoming Remarks
Luke Stewart, Senior Director, Product Management, SAAMA TECHNOLOGIES
Digital Therapeutics: Software As Treatment
  • Discuss how machine learning can be leveraged to personalize treatment and engage patients
  • Hear how digital therapeutics can produce clinical outcomes comparable to or better than drugs
  • Understand how one digital therapeutics platform can be leveraged to target multiple indications (Click’s platform targets depression, insomnia, chronic pain, and more)
  • Learn how the Clickometrics® platform enables our programs to tailor the therapeutic to best fit each individual patient
Christopher Jordan, Chief Technology Officer, CLICK THERAPEUTICS
Utilize Predictive Analytics to Manage Healthcare Outcomes
  • Hear about a patient monitoring platform that detects sepsis and fluid overload in ICU patients via urinary catheter
  • Learn how Potrero Medical has found the balance between innovative technology adoption and meeting business goals
  • Understand how Potrero Medical has utilized predictive models to address patients needs
Kelly Stanton, Senior Data Scientist, POTRERO MEDICAL
Address Pharma’s Big Data Problem and Even Bigger Text Problem
  • Provide a broad perspective on different Natural Language Processing (NLP) problems in Pharma and how that compares with other industries
  • Review different Deep Learning techniques that can be used to solve Pharma NLP problems
  • Outline how Saama went about solving Adverse Drug Event (ADE) extraction problems
Malaikannan Sankarasubbu, VP of AI Research, SAAMA TECHNOLOGIES
Networking Break
Clinical Data for Translational Medicine: A Machine Learning Approach
  • Implement an intelligent clinical data sharing system that combines various data redaction strategies with data access governance and analytics for translational research
  • Explain how to overcome data standards challenges, reduce the effort for SDTM conversions and improve compliance
  • Explore the general solutions, technology, and architecture of a data sharing system
Raj Bandaru, Head of Data Sciences and Analytics, BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE
Machine Learning in Drug Development: Apply Artificial Intelligence to Develop Novel Therapeutics for Neurodegenerative Diseases
  • Examine an example ML platform to improve efficiency during the drug development process
  • Leverage an innovative partnership model to maximize the use and access to a development platform
  • Understand the impact on identifying novel treatments and parsing patient populations by combining ML experts and neuroscience drug developers
Irene Choi, Ph.D., Director, Drug Discovery, VERGE GENOMICS
Networking Lunch
Transform Healthcare Delivery Through Artificial Intelligence
  • Review specific examples of utilizing AI to craft and parse the largest clinical database representing clinical information from 63 million patients collected over 16 years through electronic medical record systems
  • Explore OSU Center for Health Systems Innovation’s efforts to apply AI approaches to the transformation of healthcare delivery, emphasizing on rural healthcare
William D. Paiva, Ph.D., Executive Director, Center for Health Systems Innovation (CHSI), OKLAHOMA STATE UNIVERSITY
Networking Break
Integrate Artificial Intelligence Across the Commercialization Value Chain
  • Review how ML and NLP are being used to improve target identification, candidate selections and formulation development
  • Improve treatment adherence and increase patient recruitment efficiency in clinical trial design
  • Apply AI augmented reality system to the manufacturing process/upscaling and postmarket surveillance
Ronald Dorenbos, Associate Director Materials and Innovation, TAKEDA
Utilize AI Applications to Ensure Pharmacovigilance at Every Step of the Drug Development Process
  • Elevate pharmacovigilance operations through technological innovations and internal collaborations
  • Identify and limit side effects of marketed drugs through AI systems
  • Enhance PV performance and reporting by utilizing developing technologies
Dr. Douglas Fleming, Therapeutic Area Head, Immunology, at Global Pharmacovigilance and Epidemiology, BRISTOL-MYERS SQUIBB
Day One Concludes
Day Two | Wednesday, November 7, 2018
Continental Breakfast and Registration Opens
Chairperson's Welcoming Remarks
Luke Stewart, Senior Director, Product Management, SAAMA TECHNOLOGIES
Bridging the Gap Between Machine Learning and Wearable Technologies in Clinical Trials
  • Operationalizing AI in clinical research - Training AI algorithms on wearable data to develop screening and monitoring tools.
  • Why use exploratory digital health endpoints in interventional studies to gather high quality patient and wearables data
  • Hear how MyoKardia’s cross-functional team of translational, clinical, regulatory, and marketing experts collaborated to rapidly develop digital health tools.
Charles Wolfus, Vice President, Digital Health and Business Operations, MYOKARDIA
Networking Break
Real-World AI and Drug Repositioning: A Perfect Match for Drug Development
  • Not all AI platforms are the same: Understand how to find the right one
  • How AI-driven repositioning can impact key aspects of healthcare relevant to the discovery and development of drugs and in the context of the right patient subpopulations, all the way from lab bench to the point of care
  • Review examples and case studies, including Biovista’s Project Prodigy AI
Aris Persidis, President, BIOVISTA
Define Blockchain Healthcare Needs and Strategies for Adoption
  • Define appropriate blockchain architecture for regulatory compliance
  • Engage healthcare’s various stakeholders effectively for implementation and adoption
  • Review successful blockchain in healthcare uses cases as well examples of pitfalls to date
Rishi Madhok, M.D., Chief Executive Officer and Co-Founder, BITMED
Networking Lunch
Leveraging Machine Learning and AI to Drive Process Improvement at Bayer
  • Understand the implications of modeling of clinical trials in outcomes with machine learning to improve trial efficiencies
  • Hear how risk-based scheduling and planning is being used for clinical trial process optimization
  • Learn about novel deep learning models for subject enrollment and sales forecasting
Kevin Hua, Senior Manager A.I./Machine Learning Development, BAYER
Artificial Intelligence Impact on Healthcare From Drug Discovery to Digital Health
  • Identify strategies for alliance management with technologies providers that understand the current medical needs and the future platforms of operations
  • Develop strategies to ensure data management and analysis converts to increased patient care or improved healthcare outcomes
  • Outline potential downfalls of direct-to-consumer healthcare devices and how to avoid pitfalls
Georgia Mitsi, MBA, Ph.D., Senior Director, Head of Digital Health Care Initiatives, SUNOVION PHARMACEUTICALS INC.
Digitally Detecting Developing Diseases
  • Hear how BioTrillion is developing a health technology platform called BioEngine4D by applying computational learning and AI to clinical health data and novel LIFEdata, now accessible through the ubiquity of multi-modality sensors present in everyday consumer smart devices
  • Consider how ML models can examine physiologic, non-molecular biomarkers to predict disease presence
  • Review how developing diseases exhibit a dynamic pattern of progression that can be identified through a uniquely identifiable signature and are continually measured and tracked by existing sensors
  • Shift disease detection earlier in the health-time continuum — pre-symptomatically — from developed to developing using predictive analytics
Savan Devani, Founder and CEO, BIOTRILLION
Chairperson's Closing Remarks
Luke Stewart, Senior Director, Product Management, SAAMA TECHNOLOGIES
Conference Concludes

Request Event Documentation

Get all of the conference event! Get Event Documentation